$8.99+0.13|(+1.47%)
52W H: 9.4852W L: 1.91Beta: 0.93

About Alpha Teknova Inc

  • Industry: Life Sciences Tools & Services
  • Exchange: NASDAQ NMS - GLOBAL MARKET
  • Country: US
  • Website: https://www.teknova.com/

Frequently Asked Questions

What is the 52-week range for TKNO?

The 52-week high is $9.48 and the 52-week low is $1.91.

What is the P/E ratio for TKNO?

The P/E ratio data is currently unavailable.

What is the dividend yield for TKNO?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -24.94%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -38.37%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 2.96.

Analyst Recommendation Trends

Wall Street analyst consensus for TKNO over the last few months:

2026-09-01
Buy: 6
S.Buy: 5
Hold: 2
Sell: 0
2026-08-01
Buy: 5
S.Buy: 4
Hold: 3
Sell: 0
2026-07-01
Buy: 5
S.Buy: 4
Hold: 3
Sell: 0
2026-06-01
Buy: 5
S.Buy: 4
Hold: 3
Sell: 0

Latest TKNO News

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissionsHOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc. (“Pluristyx”), today announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration (F

Yahoo10/2/2026

All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo10/1/2026

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo9/22/2026

Jefferies Initiates Coverage On Alpha Teknova with Buy Rating, Announces Price Target of $9

Jefferies analyst Matthew Stanton initiates coverage on Alpha Teknova (NASDAQ:TKNO) with a Buy rating and announces Price Target of $9.

Benzinga9/17/2026

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround timeHOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today intr

Yahoo9/16/2026

Related Stocks (Peers)

Companies operating in similar sectors to TKNO:

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-07-14DEMSKI MARTHA J+12,000--
2026-07-14DEMSKI MARTHA J-12,000--
2026-06-01Vos Alexander+55,000--
2026-06-01ROBERTSON BRETT+55,000--
2026-06-01DEMSKI MARTHA J+55,000--
2026-03-06Gunstream Stephen+26,000$2.1462$55,801
2026-03-06Lowell Matthew+40,000$2.1904$87,616
2026-02-15Gunstream Stephen+429,000--
2026-02-15Lowell Matthew+171,000--
2026-02-15Terrill Damon+148,000--